The first results of the EVAL study are expected to be published in the fourth quarter of 2022
Launch of a study to assess the impact of Nociscan on the cost of care for patients with chronic low back pain (CLBP)
Promising initial clinical evaluations with 87% of patients treated for discs identified as painful by Nociscan continuing to show significant clinical improvements at a two-year follow-up
BROOMFIELD, CO/ACCESSWIRE/July 20, 2022/ Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON)(NASDAQ: ACONW), a health technology company that leverages proprietary augmented intelligence biomarkers and algorithms to help physicians identify the location of chronic low back pain, today announced the launch of the Value Analytics Study economics of low back pain (EVAL); a rigorous health economic study to assess the impact of the Nociscan solution on the cost of caring for patients with chronic low back pain (Chronic Low Back Pain). The University of California, San Francisco and the Center for Disruptive Musculoskeletal Innovations (CDMI), which is funded by the National Science Foundation, are conducting the study using outcome data from previously published clinical studies.
The first results of the EVAL study are expected to be published in the fourth quarter of 2022. The company expects the results of this study to provide strong economic support for the use of Nociscan in the evaluation of CLBP and to use these data to accelerate coverage decisions for insurance companies and self-insured employers.
“Throughout my career, I have been interested in the link between health economics and spine care. Chronic low back pain has a significant health and social cost, and the EVAL study is valuable in guiding a evidence-based approach to appropriate care for patients with symptomatic disc degeneration,” said Dr. Sigurd Berven, professor of orthopedic surgery at the University of California San Francisco School of Medicine. “Aclarion is truly a breakthrough technology in the assessment of CLBP, and the EVAL study will provide a clear picture of the economic impact Nociscan can have for the US healthcare system and for the appropriate management of patients with CLBP. low back pain.
Nociscan is the first evidence-based SaaS platform to noninvasively help physicians distinguish between tender and nontender discs in the lumbar spine. Through a cloud connection, Nociscan receives Magnetic Resonance Spectroscopy (MRS) data from an MRI machine for each lumbar disc assessed. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers that have been shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to highlight whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical information about the location of a patient’s low back pain, giving physicians the clarity needed to optimize treatment strategies.
“Aclarion is committed to its mission to improve the lives of people who suffer from debilitating back pain,” said Brent Ness, CEO and Director of the Board of Aclarion. “Nociscan helps physicians improve treatment strategies by identifying the source of a patient’s low back pain. Early clinical evaluations have been very promising with 87% of patients who were treated at discs identified as painful by Nociscan continuing to show significant clinical improvements at two Compare this to surgical success rates of between 41-57% for conventional low back pain procedures and you can see the incredible opportunity for Nociscan to significantly reduce the cost of care for CLBP patients. , which represents a significant portion of the single largest health care expenditure in the U.S. The EVAL study is an important body of work for everyone involved in treating patients with CLBP, and we look forward to the results of this academic work.
Chronic low back pain is a global health problem, with an estimated 255 million people worldwide suffering from degenerative spinal diseases and low back pain. In the United States alone, more than $134 billion is spent each year on lower back and neck pain. Conventional imaging and diagnostics provide valuable structural information about the condition of a patient’s spine, but struggle to identify the source of pathogenic pain, contributing to low surgical success rates (41 57%), especially for people with discogenic low back pain.,
“An evidence-based process for accurately identifying a source of low back pain is valuable for improving the cost-effectiveness of operative and nonoperative management strategies,” said Leslie Wilson, PhD, professor in the Department of Medicine and the Department of Clinical Medicine. Pharmacy at the University of California, San Francisco.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The company first addresses the chronic low back pain market with Nociscan, the first evidence-based SaaS platform to noninvasively help physicians distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives Magnetic Resonance Spectroscopy (MRS) data from an MRI machine for each lumbar disc assessed. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers that have been shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical information about the location of a patient’s low back pain, giving physicians the clarity needed to optimize treatment strategies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the Company’s current expectations regarding future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates”, “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the Company’s current plans and expectations, as well as the results of operations and the future financial situation. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Prospectus dated April 21, 2022 as filed with the Securities and Exchange Commission on April 25, 2022 pursuant to Rule 424(b)(4). ), as well as other information contained in the Prospectus and subsequent filings with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The information set forth above has been prepared by Aclarion and reflects Aclarion’s opinion only. Nothing in this statement should be construed to imply endorsement or approval of Aclarion or any of its products by the regents of the University of California, its officers, agents and employees. Additionally, Dr. Sigurd Berven and Leslie Wilson, PhD. will not receive any compensation from Aclarion.
Kirin M. Smith
PCG Advisory, Inc.
 Ravindra VM, Global Spine Journal (2018) 8(8): 784-794
 Wei J, Song Y et al. Comparison of total artificial disc replacement versus fusion for lumbar disc disease: a meta-analysis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325
 Ibrahim T, Tieyjeh IM, et al. Surgical versus non-surgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113
THE SOURCE: Clarion Inc.
See the source version on accesswire.com: